Armata Pharmaceuticals (ARMP) Q2 2025 earnings summary

Executive summary

• Focused on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections, with three completed Phase 2 trials and two lead candidates (AP-PA02 and AP-SA02) targeting chronic and acute bacterial infections.

• Achieved positive topline results from Phase 1b/2a diSArm trial for AP-SA02 in S. aureus bacteremia, demonstrating significant efficacy and safety, and promising results from Phase 2 Tailwind study for AP-PA02 in non-CF bronchiectasis.

• Secured $15 million credit agreement maturing in 2029 and received $4.65 million in additional non-dilutive funding, increasing total awards and supporting ongoing development.

• Advanced bacteriophage science with presentations at major research symposia.

• Substantial doubt exists about the ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months; additional capital is required.

Financial highlights

• Grant and award revenue was $2.2 million for Q2 2025, up from zero in Q2 2024, and $2.7 million for the first half of 2025, up from $1.0 million in the prior year.

• Operating expenses decreased 24.3% year-over-year to $9.0 million for Q2 2025 and 23.4% to $17.7 million for the first half of 2025.

• Net loss for Q2 2025 was $16.3 million, compared to net income of $9.0 million in Q2 2024, primarily due to non-cash charges and a loss in fair value of the Convertible Loan.

• Cash and cash equivalents were $4.3 million as of June 30, 2025, down from $9.3 million at year-end 2024.

• Loss from operations improved to $6.8 million from $11.9 million year-over-year.

Outlook and guidance

• Existing cash is insufficient to fund operations for the next 12 months; management is seeking additional capital through equity, debt, grants, or strategic partnerships.

• Plans to resume clinical development of AP-PA02 for NCFB and initiate a pivotal trial for AP-SA02 in bacteremia are contingent on securing further funding, with a Phase 3 trial design meeting planned with the FDA in H2 2025.